April 17, 2017 4:58pm
… It’s tough to tell the truth everyday as I need some news to justify share pricing while …
Q1/16 financial results are teeing up
… And valuations seesaw with resistance
Pre-open indications: 0 hit and 5 miss <made money by selling into strength but, there was money left on the table for another day as safety is my middle name>
Out and about: Juno Therapeutics (JUNO) kicked its R&D section into high gear following disappointing results with one of its once-promising lead CAR-T cancer treatment JCAR015. JUNO has tapped former Genentech (RHHBY) scientist Sunil Agarwal to get R&D back on track.
I answer one question, in which company should investors commit and keep their money
Get breaking news and the sector’s daily interpretation in your email …
Members only. Please login.